Figure 3.
Figure 3. Canine F.IX expression in hemophilia B dogs following ILP delivery of AAV-2 vector. (A) Canine F.IX antigen levels and (B) activated partial thromboplastin times (aPTTs) in plasma samples of hemophilia B dogs as a function of time after delivery of AAV-CMV-cF.IX. Dog D99 () was injected with 3.7 × 1012 vg/kg, dog F57 (×) with 1.7 × 1012 vg/kg, and dog H08 (▪) with 3.0 × 1012 vg/kg, by isolated limb perfusion, accompanied by transient immunosuppression. Dog E59 (▴) was injected by peripheral vein with 2.9 × 1012 vg/kg. Dog E60 (○) was injected at 3.9 × 1012 vg/kg by ILP, without immunosuppression. Dog B48 () was injected by direct intramuscular injection with 3.4 × 1012 vg/kg. Arrow denotes infusion of canine plasma, resulting in transient spike in cF.IX and drop in aPTT.

Canine F.IX expression in hemophilia B dogs following ILP delivery of AAV-2 vector. (A) Canine F.IX antigen levels and (B) activated partial thromboplastin times (aPTTs) in plasma samples of hemophilia B dogs as a function of time after delivery of AAV-CMV-cF.IX. Dog D99 () was injected with 3.7 × 1012 vg/kg, dog F57 (×) with 1.7 × 1012 vg/kg, and dog H08 (▪) with 3.0 × 1012 vg/kg, by isolated limb perfusion, accompanied by transient immunosuppression. Dog E59 (▴) was injected by peripheral vein with 2.9 × 1012 vg/kg. Dog E60 (○) was injected at 3.9 × 1012 vg/kg by ILP, without immunosuppression. Dog B48 () was injected by direct intramuscular injection with 3.4 × 1012 vg/kg. Arrow denotes infusion of canine plasma, resulting in transient spike in cF.IX and drop in aPTT.

Close Modal

or Create an Account

Close Modal
Close Modal